1. Home
  2. PSNYW vs INDP Comparison

PSNYW vs INDP Comparison

Compare PSNYW & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

SELL

Current Price

$3.77

Market Cap

398.5M

ML Signal

SELL

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

SELL

Current Price

$2.57

Market Cap

438.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PSNYW
INDP
Founded
2017
2000
Country
Sweden
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.5M
438.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
PSNYW
INDP
Price
$3.77
$2.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.6K
★ 563.6K
Earning Date
03-06-2025
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.49
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.92
52 Week High
$9.08
$5.96

Technical Indicators

Market Signals
Indicator
PSNYW
INDP
Relative Strength Index (RSI) 43.10 50.79
Support Level $2.21 $2.24
Resistance Level $3.99 $2.96
Average True Range (ATR) 0.20 0.35
MACD -0.05 -0.06
Stochastic Oscillator 33.33 45.35

Price Performance

Historical Comparison
PSNYW
INDP

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: